Literature DB >> 30840079

Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Arlene E Chung1,2,3, Kimberly Shoenbill2,4, Sandra A Mitchell5, Amylou C Dueck6, Deborah Schrag7, Deborah W Bruner8, Lori M Minasian5, Diane St Germain5, Ann M O'Mara5, Paul Baumgartner9, Lauren J Rogak10, Amy P Abernethy11,12, Ashley C Griffin2, Ethan M Basch1,2,3,10.   

Abstract

OBJECTIVE: The study sought to describe patient-entered supplemental information on symptomatic adverse events (AEs) in cancer clinical research reported via a National Cancer Institute software system and examine the feasibility of mapping these entries to established terminologies.
MATERIALS AND METHODS: Patients in 3 multicenter trials electronically completed surveys during cancer treatment. Each survey included a prespecified subset of items from the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Upon completion of the survey items, patients could add supplemental symptomatic AE information in a free text box. As patients typed into the box, structured dropdown terms could be selected from the PRO-CTCAE item library or Medical Dictionary for Regulatory Activities (MedDRA), or patients could type unstructured free text for submission.
RESULTS: Data were pooled from 1760 participants (48% women; 78% White) who completed 8892 surveys, of which 2387 (26.8%) included supplemental symptomatic AE information. Overall, 1024 (58%) patients entered supplemental information at least once, with an average of 2.3 per patient per study. This encompassed 1474 of 8892 (16.6%) dropdowns and 913 of 8892 (10.3%) unstructured free text entries. One-third of the unstructured free text entries (32%) could be mapped post hoc to a PRO-CTCAE term and 68% to a MedDRA term. DISCUSSION: Participants frequently added supplemental information beyond study-specific survey items. Almost half selected a structured dropdown term, although many opted to submit unstructured free text entries. Most free text entries could be mapped post hoc to PRO-CTCAE or MedDRA terms, suggesting opportunities to enhance the system to perform real-time mapping for AE reporting.
CONCLUSIONS: Patient reporting of symptomatic AEs using a text box functionality with mapping to existing terminologies is both feasible and informative.
© The Author(s) 2019. Published by Oxford University Press on behalf of the American Medical Informatics Association. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  MedDRA; PRO-CTCAE; free text; patient-reported outcomes; symptomatic adverse events

Mesh:

Substances:

Year:  2019        PMID: 30840079      PMCID: PMC6402312          DOI: 10.1093/jamia/ocy169

Source DB:  PubMed          Journal:  J Am Med Inform Assoc        ISSN: 1067-5027            Impact factor:   4.497


  14 in total

1.  Text mining for adverse drug events: the promise, challenges, and state of the art.

Authors:  Rave Harpaz; Alison Callahan; Suzanne Tamang; Yen Low; David Odgers; Sam Finlayson; Kenneth Jung; Paea LePendu; Nigam H Shah
Journal:  Drug Saf       Date:  2014-10       Impact factor: 5.606

2.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

3.  Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Authors:  Ethan Basch; Bryce B Reeve; Sandra A Mitchell; Steven B Clauser; Lori M Minasian; Amylou C Dueck; Tito R Mendoza; Jennifer Hay; Thomas M Atkinson; Amy P Abernethy; Deborah W Bruner; Charles S Cleeland; Jeff A Sloan; Ram Chilukuri; Paul Baumgartner; Andrea Denicoff; Diane St Germain; Ann M O'Mara; Alice Chen; Joseph Kelaghan; Antonia V Bennett; Laura Sit; Lauren Rogak; Allison Barz; Diane B Paul; Deborah Schrag
Journal:  J Natl Cancer Inst       Date:  2014-09-29       Impact factor: 13.506

4.  Big Data and Pharmacovigilance: Data Mining for Adverse Drug Events and Interactions.

Authors:  C Lee Ventola
Journal:  P T       Date:  2018-06

5.  Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions.

Authors:  Rave Harpaz; Santiago Vilar; William Dumouchel; Hojjat Salmasian; Krystl Haerian; Nigam H Shah; Herbert S Chase; Carol Friedman
Journal:  J Am Med Inform Assoc       Date:  2012-10-31       Impact factor: 4.497

6.  Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections.

Authors:  Janice Kim; Harpreet Singh; Kassa Ayalew; Kristina Borror; Michelle Campbell; Laura Lee Johnson; Alyson Karesh; Ni A Khin; Joanne R Less; Jerry Menikoff; Lori Minasian; Sandra A Mitchell; Elektra J Papadopoulos; Richard L Piekarz; Kevin A Prohaska; Susan Thompson; Rajeshwari Sridhara; Richard Pazdur; Paul G Kluetz
Journal:  Clin Cancer Res       Date:  2017-12-13       Impact factor: 12.531

Review 7.  Electronic toxicity monitoring and patient-reported outcomes.

Authors:  Ethan M Basch; Bryce B Reeve; Sandra A Mitchell; Stephen B Clauser; Lori Minasian; Laura Sit; Ram Chilukuri; Paul Baumgartner; Lauren Rogak; Emily Blauel; Amy P Abernethy; Deborah Bruner
Journal:  Cancer J       Date:  2011 Jul-Aug       Impact factor: 3.360

8.  Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.

Authors:  Ethan Basch; Stephanie L Pugh; Amylou C Dueck; Sandra A Mitchell; Lawrence Berk; Shannon Fogh; Lauren J Rogak; Marcha Gatewood; Bryce B Reeve; Tito R Mendoza; Ann M O'Mara; Andrea M Denicoff; Lori M Minasian; Antonia V Bennett; Ann Setser; Deborah Schrag; Kevin Roof; Joan K Moore; Thomas Gergel; Kevin Stephans; Andreas Rimner; Albert DeNittis; Deborah Watkins Bruner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-02-10       Impact factor: 7.038

9.  Deep learning for pharmacovigilance: recurrent neural network architectures for labeling adverse drug reactions in Twitter posts.

Authors:  Anne Cocos; Alexander G Fiks; Aaron J Masino
Journal:  J Am Med Inform Assoc       Date:  2017-07-01       Impact factor: 4.497

10.  The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis.

Authors:  Leàn Rolfes; Florence van Hunsel; Laura van der Linden; Katja Taxis; Eugène van Puijenbroek
Journal:  Drug Saf       Date:  2017-07       Impact factor: 5.606

View more
  19 in total

1.  Patient-Reported Outcomes in Surgical Oncology: An Overview of Instruments and Scores.

Authors:  Joseph D Phillips; Sandra L Wong
Journal:  Ann Surg Oncol       Date:  2019-08-28       Impact factor: 5.344

Review 2.  Evolution of Hematology Clinical Trial Adverse Event Reporting to Improve Care Delivery.

Authors:  Tamara P Miller; Richard Aplenc
Journal:  Curr Hematol Malig Rep       Date:  2021-03-30       Impact factor: 3.952

3.  A comparison of the efficacy and safety of ixazomib and lenalidomide combined with dexamethasone in the treatment of multiple myeloma.

Authors:  Zhipan Zheng; Kai Lin
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

4.  Patient-Reported Outcomes for Tolerability Assessment in Phase I Cancer Clinical Trials.

Authors:  Ethan Basch; Christina Yap
Journal:  J Natl Cancer Inst       Date:  2021-08-02       Impact factor: 13.506

5.  The Head and Neck Survivorship Tool (HN-STAR) Trial (WF-1805CD): A protocol for a cluster-randomized, hybrid effectiveness-implementation, pragmatic trial to improve the follow-up care of head and neck cancer survivors.

Authors:  Talya Salz; Jamie S Ostroff; Chandylen L Nightingale; Thomas M Atkinson; Eleanor C Davidson; Sankeerth R Jinna; Anuja Kriplani; Glenn J Lesser; Kathleen A Lynch; Deborah K Mayer; Kevin C Oeffinger; Sujata Patil; Andrew L Salner; Kathryn E Weaver
Journal:  Contemp Clin Trials       Date:  2021-05-21       Impact factor: 2.261

6.  Gain and loss from transcatheter intra-arterial limb infusion of cisplatin for extremity osteosarcoma: a retrospective study of 99 cases in the past six years.

Authors:  Lu Xie; Jie Xu; Sen Dong; Jian Gao; Xiaodong Tang; Taiqiang Yan; Rongli Yang; Wei Guo
Journal:  Cancer Manag Res       Date:  2019-07-30       Impact factor: 3.989

7.  Patient and clinician opinions of patient reported outcome measures (PROMs) in the management of patients with rare diseases: a qualitative study.

Authors:  Olalekan Lee Aiyegbusi; Fatima Isa; Derek Kyte; Tanya Pankhurst; Larissa Kerecuk; James Ferguson; Graham Lipkin; Melanie Calvert
Journal:  Health Qual Life Outcomes       Date:  2020-06-10       Impact factor: 3.186

8.  Racial differences in user experiences and perceived value of electronic symptom monitoring in a cohort of black and white bladder and prostate cancer patients.

Authors:  Cleo A Samuel; Angela B Smith; Wendi Elkins; Jennifer Richmond; Zahra Mahbooba; Ethan Basch; Antonia V Bennett; Arlene E Chung; Mattias Jonsson; Ronald C Chen; Bryce B Reeve
Journal:  Qual Life Res       Date:  2020-02-28       Impact factor: 3.440

9.  Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer.

Authors:  Chen-Yu Huang; Min Cheng; Na-Rong Lee; Hsin-Yi Huang; Wen-Ling Lee; Wen-Hsun Chang; Peng-Hui Wang
Journal:  Int J Environ Res Public Health       Date:  2020-03-26       Impact factor: 3.390

10.  Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.

Authors:  Min Cheng; Howard Hao Lee; Wen-Hsun Chang; Na-Rong Lee; Hsin-Yi Huang; Yi-Jen Chen; Huann-Cheng Horng; Wen-Ling Lee; Peng-Hui Wang
Journal:  Int J Environ Res Public Health       Date:  2019-11-29       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.